Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer
CAMBRIDGE, Mass., September 04, 2019 – Beam Therapeutics, a biotechnology...
The human genome is made up of billions of nucleobases, or “bases,” represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Starting with our founders and funders, we’re building a world-class team to develop precision genetic medicines through DNA and RNA base editing. Join us.
The Formulation Development group at Beam is seeking a highly motivated Research Associate/ Senior Research Associate. The incumbent will contributeRead More
Beam is seeking an innovative, collaborative, and accomplished mass spectrometrist to support the analytical development of novel base editing therapies.Read More
The successful candidate will assist in the development and execution of cell-based bioassays and immunoassays within the Analytical Development teamRead More
26 Landsdowne Street
Cambridge, MA 02139